uniQure (QURE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
Annual General Meeting scheduled for June 10, 2026, in Amsterdam, Netherlands.
Proxy materials and 2025 annual report are available online for shareholder review and voting.
Shareholders are encouraged to vote electronically or request paper materials by May 29, 2026.
Voting matters and shareholder proposals
Adoption of 2025 Dutch statutory annual accounts and discharge of Board liability for 2025.
Reappointment of three non-executive directors: Madhavan Balachandran, Jack Kaye, and Leonard Post, Ph.D.
Board designated as competent body for share issuance, preemptive rights exclusion, and share repurchase.
Appointment of KPMG Accountants N.V. as external auditor for fiscal year 2026.
Amendments to Articles of Association regarding company regime, share capital, and federal forum selection.
Board of directors and corporate governance
Board recommends voting FOR all proposals except Proposal 11, where 1 YEAR is recommended for advisory vote frequency.
Amendments proposed to reflect Dutch large company regime in Articles of Association.
Latest events from uniQure
- FDA alignment enables AMT-130 BLA submission in Q1 2026, using Enroll-HD as external control.QURE
Status Update9 Jul 2026 - AMT-130 slowed disease progression by 80% and reduced neurodegeneration biomarkers at 24 months.QURE
Study Update8 Jul 2026 - FDA alignment enables accelerated approval using Phase I/II data and cUHDRS as an endpoint.QURE
Study Update8 Jul 2026 - Q1 2026 brought higher revenue, a $53.5M net loss, and key regulatory and pipeline milestones.QURE
Q1 202612 May 2026 - Shareholders will vote on governance, compensation, capital structure, and policy changes.QURE
Proxy filing27 Apr 2026 - Shareholders will vote on director reappointments, compensation, auditor, and key governance changes.QURE
Proxy filing16 Apr 2026 - Huntington's therapy slowed progression in trials, but FDA seeks new phase III data.QURE
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - 2025 saw $16.1M revenue, strong cash, clinical progress, and ongoing regulatory hurdles.QURE
Q4 20252 Mar 2026 - AMT-130 achieved significant clinical milestones in Huntington's, supporting BLA submission plans.QURE
Corporate presentation3 Feb 2026